- Home
- FRPH vs EYPT Comparison
FRPH vs EYPT Comparison
Compare FRPH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRPH | EYPT |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | FRPH | EYPT |
|---|---|---|
| Price | $22.74 | $17.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.60 |
| AVG Volume (30 Days) | 76.5K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $33,049,999.00 | ★ $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $93.20 | ★ N/A |
| Revenue Growth | ★ 5.21 | N/A |
| 52 Week Low | $21.68 | $3.91 |
| 52 Week High | $31.99 | $19.11 |
Technical Indicators
Market Signals| Indicator | FRPH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 55.47 |
| Support Level | $22.63 | $17.79 |
| Resistance Level | $23.03 | $18.50 |
| Average True Range (ATR) | 0.48 | 0.95 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 37.01 | 46.87 |
Price Performance
Historical ComparisonAbout FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.